

## **References**

### **L-102**

1. Hayes, Inc. Hayes Medical Technology Directory Report. Pharmacogenetic and Pharmacogenomic Testing to Improve Outcomes Related to Opioid Use Disorder. Lansdale, PA: Hayes, Inc; 01/27/2022.
2. InterQual ® Level of Care Criteria 2021. Acute Care Adult. McKesson Health Solutions, LLC.
3. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. *J Addict Med.* 2020;14(2S Suppl 1): 1-91.
4. Dowell D, Ragan KR, Jones CM, et al. CDC clinical practice guideline for prescribing opioids for pain - United States. *MMWR Recomm Rep.* 2022; 71(3): 1-95.
5. Chua I, Petrides AK, Schiff GD, et al. Provider misinterpretation, documentation, and follow-up of definitive urine drug testing results. *Journal of general internal medicine.* 2020;35(1):283-290.
6. Penney SR, McLaren S, Wilkie T. Urine drug screening in a forensic mental health population: frequency and clinical utility in risk management. *Journal of Forensic Psychiatry & Psychology.* 2021;32(4):431-448.
7. Zijp, T. R., Izzah, Z., Åberg, C., et. al Clinical value of emerging bioanalytical methods for drug measurements: a scoping review of their applicability for medication adherence and therapeutic drug monitoring. *Drugs,* 2021;1-20.